Wegovy (semaglutide injection once weekly) / Novo Nordisk, Emcure - LARVOL DELTA

Singapore's Health Sciences Authority (HSA) has approved Wegovy (once-weekly injectable semaglutide 2.4 mg) as the first approved treatment in Singapore for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) and moderate to advanced liver fibrosis (F2–F3), as an adjunct to a reduced-calorie diet and increased physical activity (PRNewswire) - "The approval is based on the planned interim Week 72 efficacy analysis of Novo's ESSENCE trial, a randomised, double-blind, placebo-controlled phase 3 study."

Approval • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

SWIFT: Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: The Methodist Hospital Research Institute

New P2 trial • Endometrial Cancer • Genetic Disorders • Long-acting Reversible Contraceptives • Obesity • Oncology • Solid Tumor

Novo Nordisk says Wegovy approved in China for liver disease MASH (Reuters)

China approval • Metabolic Dysfunction-Associated Steatohepatitis

Novo to share real-world and clinical data including Wegovy pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026 (GlobeNewswire) - "New data will highlight the breadth of semaglutide evidence across the cardiometabolic spectrum, including obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease, and new data on Wegovy pill, Wegovy 7.2 mg and Ozempic 2.0 mg. Real-world evidence from the OCTANE study will provide insights into Wegovy pill use in adults with overweight or obesity, including weight outcomes, treatment switching and patient-reported outcomes. CagriSema and amylin-based pipeline data will provide new insights into appetite regulation, eating behaviour, food noise, body composition and bone health (bone remodelling mechanisms). The data will advance our understanding of the underlying biology of obesity and type 2 diabetes and inform next-generation cardiometabolic innovation."

Clinical data • Cardiovascular • Obesity • Type 2 Diabetes Mellitus

Study: Novo’s Wegovy cuts obesity rates in children under 12 (Firstwordpharma Press Release) - "The Phase III STEP Young study enrolled 165 children with obesity aged 6 to <12 years, over 85% of whom at baseline had either class II or III severe obesity. Results showed that the study met its primary endpoint, with Wegovy demonstrating superior BMI reduction at week 68 compared with the placebo group. Specifically, 40.4% of those treated with Wegovy were no longer classified as having obesity at week 68, compared with none on placebo....In addition, no safety concerns were identified for growth or pubertal development; detailed findings will be presented at The Obesity Society’s annual meeting ObesityWeek in November."

P3 data • Obesity

A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) (clinicaltrials.gov) - P2 | N=210 | Not yet recruiting | Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

New P2 trial • Genetic Disorders • Obesity

Weight Loss in Adults Using Semaglutide (Real-world Study) (clinicaltrials.gov) - P=N/A | N=237211 | Completed | Sponsor: Novo Nordisk A/S | Recruiting ➔ Completed | N=35000 ➔ 237211

Enrollment change • Real-world evidence • Trial completion • Genetic Disorders • Obesity

PLATEAU: Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (clinicaltrials.gov) - P2 | N=239 | Active, not recruiting | Sponsor: Veru Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Children's Hospital Los Angeles | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder • Genetic Disorders • Obesity • Pediatrics

Korea’s NGeneBio said on Friday it has started developing genetic and blood tests to predict how patients respond to glucagon-like peptide-1 (GLP-1) weight-loss drugs such as Wegovy (semaglutide) and Mounjaro (tirzepatide). (Korea Biomedical Review) - "NGeneBio said it would build a group of Korean patients with local obesity clinics to test how well the products work. It plans to use that data in drug trials and biomarker research."

Diagnostic • Obesity

OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: University of Health Sciences, Algeria

New trial • Real-world evidence • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: Emma Svennberg | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2025 ➔ Mar 2026

Enrollment open • Trial initiation date • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Obesity

Omnicom wins U.S. Media account for Ozempic and Wegovy maker Novo Nordisk (Pharmalive) - "'As reported by Adweek, Omnicom Media has won Novo Nordisk’s $520 million U.S. media planning and buying following a competitive pitch that included incumbent WPP....Omnicom is expected to begin work in the fourth quarter of 2026.'"

Commercial • Obesity

Financial performance (Yahoo Finance) - "Q2 2026 reported sales increased by 3% at CER, with growth negatively impacted by a DKK 2.6 billion rebate provision reversal related to the 340B Drug Pricing Program in the US in Q2 2025...Q2 2026 adjusted sales increased by 7% at CER, driven by GLP-1 volume growth across geographies and favourable US rebate adjustments in the quarter...Q2 2026 reported operating profit decreased by 16% at CER, with growth negatively impacted by the US 340B rebate provision reversal in Q2 2025 as well as non-cash impairment charges of DKK 6.3 billion in Q2 2026 related to intangible pipeline assets, including monlunabant (DKK 4.0 billion)."

Sales • Obesity

Commercial highlights (Yahoo Finance) - "Wegovy pill continues its uptake in the US, and for the week ending 17 July, total weekly prescriptions exceeded 265,000. Measured by new patient starts, the Wegovy franchise remains the market leader among branded obesity medications in the US...In the coming quarters, additional Wegovy pill launches in other select markets are planned...The roll-out of Wegovy 7.2 mg single-dose pen across the EU is planned in the second half of 2026."

Commercial • Launch Europe • Launch non-US • Obesity

Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Seoul National University Hospital

New trial • CNS Disorders • Genetic Disorders • Obesity • Psychiatry

A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: Gila Therapeutics, Inc.

New P4 trial • Genetic Disorders • Obesity

PORT: Pharmacogenetics of Response to GLP1R Agonists (clinicaltrials.gov) - P1 | N=600 | Recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: Dec 2027 ➔ Apr 2028 | Trial primary completion date: Nov 2026 ➔ Apr 2027

Biomarker • Trial completion date • Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

On the 22nd, the pharmaceutical industry said Korea Novo Nordisk Pharma has applied to the Ministery of Food and Drug Safety to expand the indication for Wegovy so it can be prescribed to patients with metabolic dysfunction–associated steatohepatitis. (Chosun Biz) - "Wegovy won approval from the U.S. Food and Drug Administration (FDA) as a treatment for metabolic dysfunction–associated steatohepatitis in Aug last year. Korea Novo Nordisk Pharma was said to have submitted the same clinical data to the Ministery of Food and Drug Safety as it did to the U.S. Food and Drug Administration."

Korea filing • Metabolic Dysfunction-Associated Steatohepatitis

Crux Collaborates with Novo Nordisk to Offer Access to Wegovy and Other Obesity Management Medications (Businesswire) - "Through Crux, employers will be able to help further lower medication costs for employees by making tax-advantaged contributions via a health reimbursement arrangement (HRA), which are then applied at point of sale so there are no reimbursements or claims to process. Crux supports HRA plan design and contribution application, and helps employers meet compliance requirements, including high-deductible health plan monitoring and deductible tracking."

Commercial • Obesity

The medicines regulator has issued a new safety warning for GLP-1-based drugs, like Ozempic, which could potentially cause a rare, but serious eye disorder (ABC News) - "The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists which are used to treat type 2 diabetes and obesity: (i) Semaglutide, sold as Ozempic, Wegovy; (ii) Tirzepatide, sold as Mounjaro; (iii) Dulaglutide, sold as Trulicity; (iv) Liraglutide, sold as Saxenda. The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)."

Adverse events • Non-US regulatory • Obesity • Type 2 Diabetes Mellitus

GLP-NIT: Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity (clinicaltrials.gov) - P=N/A | N=154 | Completed | Sponsor: Goztepe Prof Dr Suleyman Yalc?n City Hospital

HEOR • New trial • Real-world evidence • Genetic Disorders • Hepatology • Liver Failure • Obesity

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) (clinicaltrials.gov) - P1 | N=71 | Recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Jul 2026 ➔ Jan 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

NN9536-4971: A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy (clinicaltrials.gov) - P=N/A | N=2701 | Enrolling by invitation | Sponsor: Novo Nordisk A/S | N=1139 ➔ 2701

Enrollment change • Genetic Disorders • Obesity

SAMARA: Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: University of California, San Diego | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2025 ➔ Dec 2026 | Trial primary completion date: Mar 2025 ➔ Dec 2026

Enrollment closed • Real-world evidence • Trial completion date • Trial primary completion date • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus